FBIO Logo

Fortress Biotech, Inc. (FBIO) 

NASDAQ
Market Cap
$48.37M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
54 of 776
Rank in Industry
43 of 433

Largest Insider Buys in Sector

FBIO Stock Price History Chart

FBIO Stock Performance

About Fortress Biotech, Inc.

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as …

Insider Activity of Fortress Biotech, Inc.

Over the last 12 months, insiders at Fortress Biotech, Inc. have bought $4.6M and sold $18,900 worth of Fortress Biotech, Inc. stock.

On average, over the past 5 years, insiders at Fortress Biotech, Inc. have bought $1.91M and sold $92,854 worth of stock each year.

Highest buying activity among insiders over the last 12 months: ROSENWALD LINDSAY A MD (President, CEO & Chairman) — $21.75M. WEISS MICHAEL S (See Remarks) — $499,997. Jin David (Chief Financial Officer) — $3,750.

The last purchase of 763,359 shares for transaction amount of $1.4M was made by ROSENWALD LINDSAY A MD (PRESIDENT, CEO & CHAIRMAN) on 2024‑09‑23.

List of Insider Buy and Sell Transactions, Fortress Biotech, Inc.

2024-09-23PurchasePRESIDENT, CEO & CHAIRMAN
763,359
4.3054%
$1.84$1.4M+15.73%
2024-07-11PurchasePresident, CEO & Chairman
5,000
$7.48$37,4180.00%
2024-07-10PurchaseChief Financial Officer
500
$7.50$3,7500.00%
2024-07-09PurchasePresident, CEO & Chairman
5,000
$7.39$36,9710.00%
2024-07-08PurchasePresident, CEO & Chairman
5,000
$7.35$36,7650.00%
2024-06-28PurchasePresident, CEO & Chairman
20,000
0.0943%
$1.64$32,7240.00%
2024-05-20Saledirector
10,000
0.0504%
$1.89$18,900-6.12%
2024-05-16PurchasePresident, CEO & Chairman
10,000
0.0532%
$1.76$17,589+5.11%
2024-01-05PurchasePresident, CEO & Chairman
50,000
0.2671%
$2.38$118,770-23.15%
2023-11-14PurchasePresident, CEO & Chairman
1.57M
1.4832%
$1.70$2.66M+46.15%
2023-11-14PurchaseSee Remarks
147,058
0.1391%
$1.70$249,999+46.15%
2023-09-26PurchasePresident, CEO & Chairman
100,000
0.0734%
$0.28$28,330-35.51%
2023-08-18PurchasePresident, CEO & Chairman
10,000
$9.34$93,400-35.51%
2023-08-17PurchasePresident, CEO & Chairman
10,000
$11.75$117,500-35.51%
2023-02-10PurchasePresident, CEO & Chairman
2.4M
2.5829%
$0.83$2M-35.51%
2023-02-10PurchaseSee Remarks
1.2M
1.2914%
$0.83$999,999-35.51%
2023-02-10Purchasedirector
299,401
0.3229%
$0.83$250,000-35.51%
2023-02-10PurchaseChief Financial Officer
35,928
0.0387%
$0.83$30,000-35.51%
2023-02-10Purchasedirector
11,976
0.0129%
$0.83$10,000-35.51%
2023-02-10Purchasedirector
11,976
0.0129%
$0.83$10,000-35.51%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$958,680.002.14479,340+35.45%+$250,894.00<0.0001
Acadian Asset Management$582,000.001.3292,058+124.34%+$322,567.23<0.01
Nantahala Capital Management Llc$556,304.001.24278,152-25.34%-$188,820.000.03
Shikiar Asset Management$446,000.000.99223,136+21.84%+$79,951.240.14
National Asset Management Inc$42.01M0.65144,700+68.31%+$17.05M0.49
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.